# Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

> **NCT07299331** · NA · NOT_YET_RECRUITING · sponsor: **Zhengzhou University** · enrollment: 50 (estimated)

## Conditions studied

- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma
- **DRUG:** Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma

## Key facts

- **NCT ID:** NCT07299331
- **Lead sponsor:** Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2031-04-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299331, "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07299331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*